DowncodedMedicare Added $39 to the High-Dose Flu Shot
The 2026-2027 Part B vaccine allowances took effect Saturday. Fluzone High-Dose, Flublok and Fluad all went from $83.49 to $122.52 across two seasons, while the manufacturers' own reported contract price sat still at $86.23. Standard dose moved by cents, and all six COVID-19 codes are still blank.
Medicare's payment for a dose of Fluzone High-Dose became $122.522 on Saturday.
Two seasons ago the same code, the same product line, the same ten-pack of single-dose syringes paid $83.492.
That is $39.03 more per dose on a vaccine your practice will put into every Medicare patient over 65 who comes through the door between now and February.
CMS posted the 2026-2027 seasonal vaccine price file on July 30 and it took effect August 1. Eight influenza codes on it carry a payment limit, three of them moved by $39, and the rest moved by cents (chart below).
Where the $39 Came From
The Part B allowance for an influenza vaccine is 95 percent of average wholesale price, per CR 14542, which CMS issued as Transmittal 13859 on July 16. A compendia list price, times 0.95, refreshed once a year.
So when the file moves, what moved is what the manufacturer published.
90662 (Fluzone High-Dose), 90673 (Flublok) and 90653 (Fluad) all land on the identical $122.522. In the 2024-2025 file they sat at $83.492, $83.492 and $83.490.
Three manufacturers, one number, both times.
90661 did something stranger. Flucelvax went from $36.849 to $66.569, up 80.7%, the largest percentage move anywhere in the file.
The standard-dose codes barely registered.
90658 gained 42 cents. 90657 gained 21 cents. 90656, the preservative-free 0.5 mL code carrying Fluarix, FluLaval and Fluzone, gained $1.54.
One caveat on the two-season framing: CMS retired the 2025-2026 file when it posted this one, and its own archive runs 2017-2018 through 2024-2025 and then jumps to the current ZIP.
The move is real across the two seasons on file. Whether it arrived in one step or two is not something the published record will tell you.
What the Allowance Sits Against
Where it gets interesting is the other public price for the same syringe.
CDC publishes what each manufacturer reports as its private sector cost per dose under the federal vaccine contracts, NDC by NDC. The 2026-2027 adult influenza table is up, and every NDC on it maps cleanly to a HCPCS code through the CMS crosswalk.
Fluzone High-Dose, NDC 49281-0126-65: $86.23. Flublok: $86.23. Fluad: $86.23.
Medicare's allowance for all three is $122.522, so the gap runs $36.29 a dose (chart below).
Standard-dose Fluzone reports at $20.878 against an allowance of $23.889, a gap of $3.01. Fluarix and FluLaval report at $21.08, a gap of $2.81.
Same fridge, same visit, same $34.62 national administration fee on G0008. The shelf you reach for is worth roughly twelve times more in spread on the 65-and-over products than on standard dose.
Both numbers are list prices and neither is your invoice, to be fair. AWP is a compendia figure nobody transacts at, and the CDC column is what the manufacturer reports rather than what a group buys at.
The direction and the size of the divergence are what carry.
Because the divergence did not come from the private side. Those three products reported $86.23 on the 2025-2026 CDC contract table and $86.23 again on the 2026-2027 one, and Flucelvax reported $43.542 both times.
The AWP-derived allowance moved. The reported contract price sat still.
The Half of the File That Is Blank
Six COVID-19 codes share the table: 91304, 91319, 91320, 91321, 91322 and 91323. One Novavax, two Pfizer, three Moderna.
Every one of them has an empty payment limit and a note reading "Effective 0x/xx/2026 - TBD."
CMS has priced the administration. The 2026 geographically adjusted COVID-19 vaccine administration rates are posted on the same page.
The product itself stays unpriced until the manufacturers release the season's formulations, and the crosswalk rows for those six carry a labeler name and nothing else: no NDC, no package size, no billable units.
90660 has a smaller version of the same problem. FluMist is priced at $30.581 with an effective date of 08/24/2026, so a claim dated in the first three weeks of the season has no allowance behind it.
Then the clock. CR 14542 tells the MACs to reprocess any claim for this season paid at an allowance other than the published 2026-2027 amounts, and to initiate the mass adjustment process by November 1, 2026.
Some of this season's vaccine line will therefore post twice.
Final Thoughts
The vaccine line is the least interesting revenue in most practices, a rounding error against the procedural book, and it gets repriced once a year by a mechanism nobody in the building touches. Which is exactly why nobody checks it.
This year that mechanism handed the 65-and-over shelf $39.03 a dose, left the COVID shelf blank on opening day, and set a November deadline for the MACs to go back and fix whatever posted in the meantime. All of it arrived in a spreadsheet CMS put on its website on a Thursday with no announcement attached.
Thanks for reading.